Antioxidant Potential of Usnea spp. Extract with Lysozyme Conjugation for the Prevention of Chronic Kidney Disease Progression
Abstract
The prevalence of chronic kidney disease worldwide has been reported to increase every year with hypertension serving as the leading cause. The recommended treatment for chronic kidney disease patients with a history of hypertension is antihypertensive medications, which could cause side effects from prolonged use. Hence, the authors sought out a possible novel modality by implementing antioxidant properties from beard lichen (Usnea spp.) extract. Literature search was conducted on trusted scientific databases, including Google Scholar, PubMed, DOAJ, and Cochrane. The pathophysiology of hypertension in the progression of chronic kidney disease could mainly be attributed to the presence of inflammation and oxidative stress, which could be attenuated by the use of antioxidants. Lichens are a class of complex living organisms resulting from a symbiosis that allows them to synthesize various beneficial phytochemicals. Usnic and stictic acid derived from Usnea spp. are part of phenolic compounds that display strong antioxidant activities. In order for these antioxidants to have a focused effect on the kidneys, a kidney-targeted drug delivery system should be considered with lysozyme conjugation being the most studied method. The combination of Usnea spp. extract’s antioxidant capabilities with lysozyme conjugation could serve as a potential novel modality in the specific prevention of chronic kidney disease progression.
Keywords: antioxidant; chronic kidney disease; lysozyme conjugation; Usnea
spp.
Full Text:
PDFReferences
Matovinović MS. PATHOPHYSIOLOGY AND CLASSIFICATION OF KIDNEY DISEASES. J Int Fed Clin Chem Lab Med 2009;20:2–11.
Kovesdy CP. Epidemiology of chronic kidney disease: an update 2022. Kidney Int Suppl 2022;12:7–11.
Hustrini NM, Susalit E, Rotmans JI. Prevalence and risk factors for chronic kidney disease in Indonesia: An analysis of the National Basic Health Survey 2018. J Glob Health 2022;12:1–10.
Bikbov B, Purcell CA, Levey AS, Smith M, Abdoli A, Abebe M, et al. Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2020;395:709–33.
Lee H, Kwon SH, Jeon JS, Noh H, Han DC, Kim H. Association between blood pressure and the risk of chronic kidney disease in treatment-naïve hypertensive patients. Kidney Res Clin Pract 2022;41:31–42.
Wang JG, Palmer BF, Anderson KV, Sever P. Amlodipine in the current management of hypertension. J Clin Hypertens 2023;25:801–7.
Sear JW. 26 - Antihypertensive Drugs and Vasodilators. Pharmacol. Physiol. Anesth. Found. Clin. Appl. Second Ed, Amsterdam: Elsevier Inc.; 2019, p. 535–55.
Xie Y, Xu P, Wang M, Zheng Y, Tian T, Yang S, et al. Antihypertensive medications are associated with the risk of kidney and bladder cancer : a systematic review and meta-analysis. Aging (Albany NY) 2020;12:1545–62.
Zambare VP, Christopher LP. Biopharmaceutical potential of lichens. Pharm Biol 2012;50:778–98.
Kıran TR, Otlu O, Karabulut AB. Oxidative stress and antioxidants in health and disease. J Lab Med 2023;47:1–11.
Gyurászová M, Gurecká R, Bábíčková J, Tóthová Ľ. Oxidative Stress in the Pathophysiology of Kidney Disease : Implications for Noninvasive Monitoring and Identification of Biomarkers. Oxidative Med Cell Longetivy 2020:11.
Y Hano EM, Pardosi L. Keanekaragaman Lumut Kerak (Lichenes) di Area Kaki Gunung Mutis. Pro-Life 2022;9:515–32.
Rasyidah. KELIMPAHAN LUMUT KERAK (LICHENS) SEBAGAI BIOINDIKATOR KUALITAS UDARA DI KAWASAN PERKOTAAN KOTA MEDAN. KLOROFIL 2018;1:88–92.
Lakhnarayan Kumar Bhagarathi, Phillip N. B. DaSilva, Gomathinayagam Subramanian, Gyanpriya Maharaj, Sushmita Kalika-Singh, Ferial Pestano, et al. An integrative review of the biology and chemistry of lichens and their ecological, ethnopharmacological, pharmaceutical and therapeutic potential. GSC Biol Pharm Sci 2023;23:092–119.
Maulidiyah M, Rachman F, Mulkiyan LOMZ, Natsir M, Nohong N, Darmawan A, et al. Antioxidant Activity of Usnic Acid Compound from Methanol Extract of Lichen Usnea sp. J Oleo Sci 2023;72:179–88.
Jannah M, A`yun Q, Afifah N, Prasetya E, Hariri MR. Usnea in West Java: a potential source of bioactive secondary metabolites. Berk Penelit Hayati 2022;28:26–31.
Maryono, Muharram, Suryani AI, Dini I. Usnic Acid Derivate from Usnea sp. and Bioactivity against Arthemia salina Leach. Mater Sci Forum 2019;967:45–50.
USDA. United States Department of Agriculture: Beard Lichen. United States Dep Agric 2023. [cited on November 21, 2023]. Available at: https://plants.usda.gov/home/plantProfile?symbol=USSP.
Jannah M, Afifah N, Hariri MR, Rahmawati A, Wulansari TYI. Study of lichen (Usnea spp.) as a traditional medicine in Bogor, West Java. Berk Penelit Hayati 2020;26:32–8.
Filbert, Koleangan HSJ, Runtuwene MRJ, Kamu VS. Penentuan Aktivitas Antioksidan Berdasarkan Nilai IC50 Ekstrak Metanol dan Fraksi Hasil Partisinya pada Kulit Biji Pinang Yaki (Areca vestiaria Giseke). J MIPA UNSRAT 2014;3:149.
Oran S, Sahin S, Sahinturk P, Ozturk S, Demir C. Antioxidant and antimicrobial potential, and HPLC analysis of stictic and usnic acids of three Usnea species from Uludag mountain (Bursa, Turkey). Iran J Pharm Res 2016;15:527–35.
Pugh D, Gallacher PJ, Dhaun N. Management of Hypertension in Chronic Kidney Disease. Drugs 2019;79:365–79.
Townsend RR. Chapter 21 - Pathophysiology of Hypertension in Chronic Kidney Disease. Chronic Ren. Dis. Second Ed, Academic Press; 2019, p. 313–22.
Zhang Z, Zhao L, Zhou X, Meng X. Role of inflammation, immunity, and oxidative stress in hypertension : New insights and potential therapeutic targets. Front Immunol 2023;13:1–18.
Sanders PW. Effect of salt intake on progression of chronic kidney disease. Curr Opin Nephrol Hypertens 2006;15:54–60.
Rubin MF, Townsend RR. Aldosterone blockade in diabetic nephropathy: Relative risks and potential promise. J Am Soc Nephrol 2009;20:2487–9.
Martens CR, Edwards DG. Peripheral Vascular Dysfunction in Chronic Kidney Disease. Cardiol Res Pract 2011;2011:267257.
Griendling KK, Camargo LL, Rios FJ, Alves-Lopes R, Montezano AC, Touyz RM. Oxidative Stress and Hypertension. Circ Res 2021;128:993–1020.
Roumeliotis S, Mallamaci F, Zoccali C. Endothelial Dysfunction in Chronic Kidney Disease , from Biology to Clinical Outcomes : A 2020 Update. J Clin Med 2020;9:2359.
Daenen K, Andries A, Mekahli D, Schepdael A Van, Jouret F, Bammens B. Oxidative stress in chronic kidney disease. Pediatr Nephrol 2019;34:975–91.
Drożdż D, Drożdż M, Wójcik M. Endothelial dysfunction as a factor leading to arterial hypertension. Pediatr Nephrol 2023;38:2973–85.
Krzemi ´nska J, Wronka M, Młynarska E, Franczyk B, Rysz J. Arterial Hypertension — Oxidative Stress and Inflammation. Antioxidants 2022;11:172.
Touyz RM, Rios FJ, Alves-Lopes R, Neves KB, Camargo LL, Montezano AC. Oxidative Stress : A Unifying Paradigm in Hypertension. Can J Cardiol 2020;36:659–70.
Sinha AD, Agarwal R. Clinical Pharmacology of Antihypertensive Therapy for the Treatment of Hypertension in CKD. Clin J Am Soc Nephrol 2019;14:757–64.
Ku E, Lee BJ, Wei J, Weir MR. Hypertension in CKD: Core Curriculum 2019. Am J Kidney Dis 2019;74:120–31.
Chen TK, Knicely DH, Grams ME. Chronic Kidney Disease Diagnosis and Management. JAMA 2019;322:1294–304.
Whelton PK, M. CR, Aronow WS, CaseyJr DE, Collins KJ, Himmelfarb CD, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task F. Hypertension 2018;71:1269–324.
Georgianos PI, Agarwal R. Hypertension in chronic kidney disease - treatment standard 2023. Nephrol Dial Transplant 2023;38:2694–703.
Beal B, Schutte AE, Neuen BL. Blood Pressure Effects of SGLT2 Inhibitors: Mechanisms and Clinical Evidence in Different Populations. Curr Hypertens Rep 2023;25:429–35.
Zhou P, Sun X, Zhang Z. Kidney – targeted drug delivery systems. Acta Pharm Sin B 2014;4:37–42.
Wang Y, Sun Y, Wang H, Liu P, Peng W, Duan Y. Synthesis of low-molecular weight protein (LMWP) lysozyme–curcumin conjugates for kidney drug targeting. J Biomater Sci 2013;24:1360–7.
Chade AR, Bidwell III GL. Novel Drug Delivery Technologies and Targets for Renal Disease. Hypertension 2022;79:1937–48.
Zheng Q, Gong T, Sun X, Zhang Z. Synthesis , Characterization and In Vitro Evaluation of Triptolide- lysozyme Conjugate for Renal Targeting Delivery of Triptolide. Arch Pharm Res 2006;29:1164–70.
Zhang Z, Zheng Q, Han J, Gao G, Liu J, Gong T, et al. The targeting of 14-succinate triptolide-lysozyme conjugate to proximal renal tubular epithelial cells. Biomaterials 2009;30:1372–81.
Zheng X, Nie Q, Feng J, Fan X, Jin Y, Chen G, et al. Kidney-targeted baicalin-lysozyme conjugate ameliorates renal fibrosis in rats with diabetic nephropathy induced by streptozotocin. BMC Nephrol 2020;21:174.
Refbacks
- There are currently no refbacks.
